Filing Flows › Comparisons › ONC vs ALNY
BeOne Medicines vs Alnylam Pharmaceuticals: ONC and ALNY compared
BeOne Medicines is the larger company: $1.9B of revenue in its latest quarter (Q3 2026) against $1.5B for Alnylam Pharmaceuticals (Q3 2026). BeOne Medicines is growing faster (+34% against +17% a year earlier). Alnylam Pharmaceuticals is more profitable, with an operating margin of 23.7% against 22.2%.
Where the money goes: ONC and ALNY
BeOne Medicines (ONC) · Q3 2026
BeOne Medicines, Q3 2026: revenue $1.9B (+34% year over year), operating margin 22.2%, net earnings $385M, operating cash flow $509M. The chart follows the revenue to costs, profit and cash.
Alnylam Pharmaceuticals (ALNY) · Q3 2026
Alnylam Pharmaceuticals, Q3 2026: revenue $1.5B (+17% year over year), operating margin 23.7%, net earnings $2.2B, operating cash flow $341M. The chart follows the revenue to costs, profit and cash.
| BeOne Medicines (ONC) | Alnylam Pharmaceuticals (ALNY) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $1.9B | $1.5B |
| Revenue growth, Y/Y | +34% | +17% |
| Gross margin | 88.5% | — |
| Operating margin | 22.2% | 23.7% |
| Net earnings | $385M | $2.2B |
| Net margin | 20.4% | 148.6% |
| Operating cash flow | $509M | $341M |
| Free cash flow | $474M | $271M |
| Market value | $624.2B | $21.6B |
| P/E | — | 8.0× |
| Analysts’ mean target | $437.57 | $302.48 |
Where the revenue comes from
BeOne Medicines
- Product revenue, net: $1.9B (98%)
- BAITUOWEI: $22.1M (1%)
- POBEVCY: $10.7M (1%)
Alnylam Pharmaceuticals
- Net product revenues: $1.3B (89%)
- Total Rare: $142M (10%)
- ONPATTRO: $19.6M (1%)
Questions
Which is bigger, BeOne Medicines or Alnylam Pharmaceuticals?
BeOne Medicines is the larger company: $1.9B of revenue in its latest quarter (Q3 2026) against $1.5B for Alnylam Pharmaceuticals (Q3 2026).
Is BeOne Medicines or Alnylam Pharmaceuticals growing faster?
BeOne Medicines is growing faster (+34% against +17% a year earlier).
Which is more profitable, BeOne Medicines or Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals is more profitable, with an operating margin of 23.7% against 22.2%.
More: BeOne Medicines earnings · how BeOne Medicines makes money · Alnylam Pharmaceuticals earnings · how Alnylam Pharmaceuticals makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 5, 2026; 10-Q filed Oct 29, 2026). Fiscal quarters can end on different dates. Not investment advice.